Press release
Cirrhosis Management Market 2017 – 2027; By Treatment, Disease Indication and End User
Cirrhosis causes the liver to shrink and harden which makes it difficult for the blood to flow into the portal vein in the liver .The liver becomes lumpy and hard, and will start to fail. Basically the liver is a hardy organ and has the ability to regenerate damaged cells. Cirrhosis develops in the liver when factors like chronic viral infections and alcohol are present for a long period of time. When this condition happens, the liver becomes scarred and injured. Scared liver cannot function properly which ultimately results in cirrhosis. The main causes of cirrhosis are excess alcohol consumption, hepatitis B, Hepatitis C and non-alcoholic fatty liver diseases.Report Overview: https://www.futuremarketinsights.com/reports/cirrhosis-management-market
There are mainly two stages of cirrhosis: compensated and decompensated. In compensated cirrhosis, there are no signs of symptoms which means there is a still presence of healthy liver cells that can meet the body needs. Whereas, decompensated cirrhosis causes symptoms such as fluid will build up in the belly (ascites), toxins will build up in the blood causing confusion, occurrence of gallstones, etc. Chances of these problems can be reduced by keeping a healthy weight, eating a low fat diet, not smoking, sticking to the treatments, not drinking. Treatments like medications, regular doctor visits and lifestyle changes can sometimes prevent or delay the further damaging of the liver. According to the National Institute of Health (NIH), cirrhosis is the 12th leading cause of death due to the diseases in the United States. Also it is estimated that cirrhosis occurs in 2 individuals per 100,000 individuals. Cirrhosis is more common in men than women.
Cirrhosis Management Market: Drivers and Restraints
The appropriate method for cirrhosis management is of major importance. Thus it is expected to be the prime factor driving growth of global cirrhosis management. Increasing prevalence of disease such as non-alcoholic fatty liver diseases is fueling the global cirrhosis management market growth. Moreover, the growing geriatric population has also lead to the significant addition in the global cirrhosis management market. However the lack of low treatment rate due to absence of signs and symptoms of cirrhosis are limiting the growth of global cirrhosis management market.
Request to view Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-5045
Cirrhosis Management Market: Overview
Based on the treatment type, the global cirrhosis management market is segmented into treating cirrhosis causes, symptomatic treatment, treatment to avoid complications and liver transplantation. Based on disease indication, the global cirrhosis management market is segmented into alcoholic liver cirrhosis and non-alcoholic liver cirrhosis. Based on end user, the global cirrhosis management market is segmented into hospitals, ambulatory surgical centers, research institutes, dialysis centers, clinics and others.
Cirrhosis Management Market: Regional Outlook
Geographically, global cirrhosis management market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America is expected to dominate global cirrhosis management market over the forecast period due to high prevalence of liver cirrhosis diseases. Western Europe is expected to be the second largest market for cirrhosis management.
Buy Cirrhosis Management Market Research Report: https://www.futuremarketinsights.com/checkout/5045
Cirrhosis Management Market: Key Players
Some of the players identified in global cirrhosis management market include B. Braun Medical Inc., Alliancells Bioscience Corporation Limited, Conatus Pharmaceuticals Inc., Stempeutics Research Pvt Ltd, Merck Sharp & Dohme Corp., Epic Research & Diagnostics, Inc., Theravance Biopharma R&D, Inc., NovaShunt AG among others
About Us
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.
Contact Us
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
T (UK): +44(0)20-7692-8790
Sales: sales@futuremarketinsights.com
Website: http://www.futuremarketinsights.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cirrhosis Management Market 2017 – 2027; By Treatment, Disease Indication and End User here
News-ID: 843351 • Views: …
More Releases from Future Market Insights

Polygon Mirror Scanner Motor Market Set to Hit USD 88.5 Million by 2035, Powered …
The global polygon mirror scanner motor market is experiencing robust growth, forecasted to rise from USD 55.9 million in 2025 to USD 88.5 million by 2035, which represents a nearly 1.6-fold increase over the assessment period. This remarkable expansion is shaped by the widespread adoption of next-generation scanning technologies and the rapid digital transformation across the printing and office equipment industries. As businesses renew their focus on speed, accuracy, and…

Global p-Hydroxybenzoic Acid Market to Approach USD 400 Million by 2035, Driven …
The global p-Hydroxybenzoic Acid (PHBA) market is entering a new era of growth, expected to rise from USD 213.0 million in 2025 to USD 399.8 million by 2035, showcasing a compound annual growth rate of 6.5%. This surge is underpinned by PHBA's flourishing adoption in polymer synthesis, textile processing, and supporting industries seeking high-performance and sustainable chemical solutions. As organizations shift towards advanced materials with enhanced durability, thermal stability, and…

Sustainable Growth Drives Castor Oil Polyol Market to USD 418.8 Million by 2035 …
The castor oil polyol market is set to reshape the landscape of bio-based chemicals, growing from a value of USD 254.7 million in 2025 to USD 418.8 million by 2035. This represents a robust CAGR of 5.1% over the decade, with expansion driven by surging demand across chemical, automotive, construction, and coatings sectors. The market's early growth, spanning 2021 to 2025, reflects steady adoption as sustainable polyols substitute petroleum-based alternatives,…

Global Fifth Wheel Coupling Market to Hit USD 1.2 Billion by 2035 Driven by Smar …
The global Fifth Wheel Coupling Market continues to evolve as the logistics and transport sectors demand more efficient, safe, and smart towing systems. Valued at USD 547.3 million in 2020 and reaching USD 672.6 million by 2024, the market is projected to expand at a 6.0% CAGR from 2025 to 2035, ultimately achieving a valuation of USD 1,238.6 million.
At the heart of this growth lies the critical role of fifth…
More Releases for Cirrhosis
Cirrhosis Pipeline: Novel Antifibrotic Therapies and Regenerative Approaches Red …
The treatment landscape for cirrhosis, a progressive liver condition marked by fibrosis and compromised liver function, is witnessing a transformative shift as biopharmaceutical companies advance beyond symptomatic management to target the underlying causes of liver damage. With no approved therapies to reverse established fibrosis, there is a growing focus on antifibrotic agents, hepatoprotective compounds, and regenerative therapies that aim to halt or reverse disease progression. Companies like Ocera Therapeutics, Gilead…
Liver Cirrhosis - Drug Pipeline Landscape, 2023
Cirrhosis, also known as liver cirrhosis or hepatic cirrhosis and end-stage liver disease, is a condition characterised by impaired liver function caused by the formation of scar tissue known as fibrosis as a result of liver disease damage. Cirrhosis is caused by alcoholic liver disease, non-alcoholic steatohepatitis (NASH), chronic hepatitis B, and chronic hepatitis C.
To Remain 'Ahead' Of Your Competitors, Request for A Sample: https://www.globalinsightservices.com/request-sample/GIS31149
Cirrhosis symptoms emerge slowly until liver…
Primary Biliary Cirrhosis - Drug Pipeline Landscape, 2023
New York, Global Insight Services have recently published a report on Primary Biliary Cirrhosis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Read more about Primary Biliary Cirrhosis - Drug Pipeline here: https://www.globalinsightservices.com/reports/primary-biliary-cirrhosis-primary-biliary-cholangitis-drug-pipeline-landscape-2022/
Primary Biliary Cirrhosis (Primary Biliary Cholangitis) is a chronic disease in which the small bile ducts in the liver become injured and inflamed…
Liver Cirrhosis - Drug Pipeline Landscape, 2023
New York, Global Insight Services have recently published a report on Liver Cirrhosis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Read more about this report: https://www.globalinsightservices.com/reports/liver-cirrhosis-drug-pipeline-landscape-2023/
Cirrhosis, also known as liver cirrhosis or hepatic cirrhosis and end-stage liver disease, is a condition characterised by impaired liver function caused by the formation of scar tissue known…
Primary Biliary Cirrhosis - Drug Pipeline Landscape, 2022
Global Insight Services have recently published a report on Primary Biliary Cirrhosis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Primary Biliary Cirrhosis (Primary Biliary Cholangitis) is a chronic disease in which the small bile ducts in the liver become injured and inflamed and are destroyed eventually.
Read more about Primary Biliary Cirrhosis - Drug Pipeline…
Global Liver Cirrhosis Market Growth 2018-2023
Market Research Report Store offers a latest published report on Liver Cirrhosis Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Liver Cirrhosis players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.To analyze the Liver Cirrhosis with respect to individual…